BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that the company is preparing to launch. A search on that date found no approval announcement, so the outcome remains open.
The FDA accepted the application for priority review, BridgeBio announced on 27 May 2026. The company says the agency does not currently plan an advisory committee meeting. If approved, BridgeBio says BBP-418 would be the first approved therapy for any form of limb-girdle muscular dystrophy (LGMD).
What Is LGMD2I/R9 and Why Does It Matter?
LGMD2I/R9 is an autosomal recessive disease caused by partial loss of function in the FKRP gene. The gene change impairs glycosylation of alpha-dystroglycan, a protein that supports muscle cells. Symptoms usually begin as weakness in the hip and shoulder muscles. Lung and heart problems often follow.
BridgeBio gives figures for people who carry two copies of the L276I variant. In adulthood, 25 per cent lose independent walking. About 10 per cent need assisted ventilation, and 30 per cent develop cardiomyopathy. Other FKRP genotypes usually start earlier and run a more severe course, according to the company.
BridgeBio estimates that about 7,000 people in the US and Europe live with LGMD2I/R9 and other addressable alpha-dystroglycanopathies. No approved therapy exists for the condition today, according to the company.
When Will the FDA Decide on BBP-418 Approval?
The target action date is 27 November 2026. BridgeBio submitted its new drug application on 30 March 2026, according to its release of that date. Priority review followed on 27 May 2026. The FDA grants it where a drug may offer a significant improvement over existing options.
A target action date is a goal, not a guarantee. The FDA can approve the drug, issue a complete response letter, or extend its review. Nobody outside the agency can say which will happen.
Andrew Tsai of Jefferies told BioSpace he sees more than 90 per cent odds of approval by the deadline. He called the lack of an advisory committee “probably a good thing”. That is one analyst’s estimate, not a finding.
BridgeBio has said it expects a US launch in late 2026 or early 2027. BioSpace reported in May 2026 that William Blair analysts used similar timing.
What Does the FORTIFY Data Behind BBP-418 Approval Show?
The filing rests on FORTIFY, a randomised, double-blind, placebo-controlled phase 3 study (NCT05775848). BridgeBio announced the 12-month interim results on 27 October 2025. The trial randomised 112 people two to one to BBP-418 or placebo, company slides show. BioSpace reports that participants were aged 12 to 60.
Efficacy results reported by the sponsor
The company’s release is the primary source for these figures. They are interim and company-reported. The release does not describe them as peer reviewed.
The primary interim endpoint was glycosylated alpha-dystroglycan, the protein the drug aims to restore. At three months, levels rose 1.8-fold from baseline, against roughly no change on placebo (p<0.0001). The increase was sustained at 12 months.
Serum creatine kinase (CK) is a marker of muscle damage. It fell by an average of 82 per cent from baseline at 12 months. The difference versus placebo was statistically significant (p<0.0001).
On the 100-metre timed test, walking velocity rose 0.14 metres per second from baseline. The gain versus placebo was 0.27 metres per second (p<0.0001). Predicted forced vital capacity rose about 3 per cent from baseline and about 5 per cent versus placebo (p=0.0071). BioSpace separately reported a 31-second difference versus placebo on the walking test.
Two caveats apply to these numbers. Interim results can change as follow-up lengthens. The protein and CK results are biomarker measures, while the walking and lung results are clinical measures. The FDA will judge how far all four support BBP-418 approval, and its review has not been published.
Katherine Mathews, Professor of Pediatrics and Neurology at the University of Iowa, was quoted in the release. She said, “These results bring enormous hope that BBP-418 might change the disease course.” That quote comes from the sponsor’s announcement, not an independent interview.
Safety and what remains unknown
The release says BBP-418 was “well-tolerated with no new or unexpected safety findings.” BridgeBio’s World Muscle Society slides, presented in October 2026, give more detail. They report no deaths and no treatment-related serious adverse events. Most adverse events were grade 1 or 2. Diarrhoea was the most common, and all cases were grade 1 or 2 and none serious.
The results remain interim. The final FORTIFY analysis comes at month 36, BridgeBio said on 29 October 2026. It expects topline results in late 2027 or early 2028.
What Would BBP-418 Approval Mean for Launch and Price?
BioSpace reported that BridgeBio already has a sales force, medical science liaisons and field reimbursement staff in place. Christine Siu, CEO of BridgeBio’s neuromuscular division, said the first market is about 150 Muscular Dystrophy Association (MDA) care centres. BioSpace reported that the company has identified more than 500 prospective US patients. BridgeBio’s third-quarter release says about 70 per cent of people with LGMD2I/R9 receive care through the MDA. Its account managers have reached more than 70 per cent of MDA centres, the company adds.
BridgeBio has not disclosed a price. Tsai modelled a list price of about US$400,000 a year. He said some observers would not be surprised by US$1 million or more. Siu said pricing would be comparable to other rare neuromuscular drugs. Payer discussions are active, she said.
A BBP-418 approval would be BridgeBio’s second launch, BioSpace reported. Its only marketed product is Attruby, approved in 2024 for ATTR-CM. Tsai said approval could bring the company to profitability by the fourth quarter of 2027. That is his projection, not company guidance. BBP-418 is the first of three BridgeBio FDA decisions due by May 2027, the company’s third-quarter release shows. Oral infigratinib has a target date of 4 February 2027 and encaleret 8 May 2027.
Siu also expects the label to require genetic testing, BioSpace reported. She does not expect that to be a barrier.
BridgeBio says it may qualify for a priority review voucher if the drug is approved. The company links this to the drug’s Rare Pediatric Disease designation. Eligibility is not guaranteed.
Gene therapies are also in development, BioSpace reported. They include Sarepta’s SRP-9003 for a different subtype, LGMD2E/R4. Bayer’s AskBio is developing AB-1003 for LGMD2I/R9. Tsai said BridgeBio “sits comfortably in pole position.”
Could BBP-418 Approval Extend Beyond the United States?
BBP-418 holds European Medicines Agency (EMA) orphan drug designation. BridgeBio plans an EMA marketing authorisation application in the first half of 2028, its third-quarter release says. That filing will rest on the final FORTIFY analysis. BioSpace reported about 3,000 patients in the US and 4,000 to 5,000 in Europe, mainly Scandinavia.
Diagnosis is a separate hurdle. An earlier article on muscular dystrophy diagnosis delays described waits of up to eight years for some LGMD patients. A treatment can only help patients who have a confirmed genetic diagnosis.
What Would Settle the BBP-418 Approval Question?
Three events would settle it. The first is the FDA action on or before 27 November. The second is the approved label, including the indication wording and any genetic testing requirement. The third is the price and payer response after launch. Readers can follow the decision on the FDA drug approval decisions tracker.
A complete response letter would reset the timeline. BridgeBio’s late 2026 or early 2027 launch guidance would then be at risk.
Longer term, BridgeBio plans studies in patients under 12 and in LGMD2M/R13 and LGMD2U/R20, according to its release. It gave no dates.
